|
|||||
|
|
TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice |
|
| Authors: | Erina Koga-Yamakawa Masashi Murata Simon J. Dovedi Robert W. Wilkinson Yosuke Ota Hiroki Umehara Eiji Sugaru Yuko Hirose Hideyuki Harada Philip J. Jewsbury Setsuko Yamamoto David T. Robinson Chiang J. Li |
| Affiliation: | 1. Sumitomo Dainippon Pharma (DSP) Cancer Institute, Sumitomo Dainippon Pharma, 3-1-98, Kasugade Naka, Konohana-ku, Osaka, 554-0022, Japan 2. Oncology Innovative Medicines and Early Development (iMed), AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, UK 5. Manchester Cancer Research Centre, Institute of Cancer Sciences, University of Manchester, Manchester, UK 6. MedImmune Ltd, Milstein Building, Granta Park, Cambridge, UK 3. Boston Biomedical, Inc., 640 Memorial Drive, Cambridge, MA, USA 4. Drug Research Division, Sumitomo Dainippon Pharma, 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |